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 Background—While screening for colorectal cancer (CRC) is a widely accepted concept 
nationally and screening rates are increasing, there are differences in screening rates between 
states and within states.
 Methods—In an effort to increase screening rates and ensure equal access based on race/
ethnicity, the New York City Department of Health and Mental Hygiene formed a coalition of 
stakeholders in 2003, with the primary focus on colonoscopy, to develop and implement strategies 
across the city to achieve this goal.
 Results—From a screening colonoscopy rate of only 42% in 2003, these concerted efforts 
contributed to achieving a screening rate of 62% by 2007, and almost 70% in 2014, with the 
elimination of racial and ethnic disparities.
 Conclusions—We provide details of how this program was successfully conceived, 
implemented and sustained in the large urban population of NYC. We hope that by sharing the 
many elements involved and the lessons that we learned, other communities may adapt our 
experiences to their own environments so that CRC screening rates can be maximized.
Precis
A strong partnership between the NYC Department of Health and Mental Hygiene and an actively 
engaged community and academic coalition successfully raised colorectal screening colonoscopy 
rates from 42% to 69% and eliminated ethnic disparities.
Keywords
colorectal cancer; colorectal cancer screening; screening colonoscopy; colorectal cancer 
prevention
 Introduction
Screening for colorectal cancer (CRC) is today a widely accepted intervention, because of its 
demonstrated effectiveness for reducing incidence and mortality. National rates for CRC 
screening test use increased from 54% in 2002 to 65% in 20121, and efforts are in place by 
over 250 public, private, and non-profit organizations to increase CRC screening to 80% by 
20182.
Colonoscopy as a screening modality was first introduced into clinical guidelines in 19973, 4, 
and became a covered benefit for Medicare beneficiaries at average risk in 2001. Shortly 
thereafter (2003), Dr. Thomas Frieden, then Commissioner of the New York City 
Department of Health and Mental Hygiene (NYC DOHMH), made CRC screening 
colonoscopy a top priority for NYC. His reasoning was: over 1,500 men and women were 
dying of CRC each year in NYC; scientific studies had demonstrated that CRC deaths can 
be prevented by screening; approximately 60% of at-risk New Yorkers were not being 
screened; and, his belief that NYC had the medical and financial resources to implement a 
colonoscopy screening program to dramatically reduce CRC mortality.5 Dr. Frieden’s 
concept was supported by Dr. Benjamin Chu, then head of the NYC Health and Hospitals 
Corporation (HHC) which is charged with providing care regardless of ability to pay. An 
Advisory Committee was formed; the main charge was to assess the potential contribution of 
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colonoscopy to NYC’s CRC prevention efforts. From this, the Citywide Colon Cancer 
Control Coalition (“C5 Coalition”) was launched as a program to increase CRC screening 
for all New Yorkers age 50 and older, with strong endorsements coming from the top health 
care leadership in the city.
This paper provides details of how C5 was conceived and how it successfully implemented 
screening colonoscopy over time. As a result, screening colonoscopy rates in NYC increased 
from 42% in 2003 (well below the national average of 52%) to 62% in 20076 a rate that was 
not reached nationally until 20121. As of 2012, the NYC screening colonoscopy rate 
increased 64% from baseline, translating into an additional 833,000 individuals screened7. 
Moreover, during this period, screening colonoscopy rates among Hispanics, for example, 
increased from 38% to 70%, considerably higher than the national rate that reached only 
48% by 20121. It is hoped that by understanding the many elements involved, other 
communities, especially in large urban settings may adapt some of the lessons learned to 
their own environments to increase CRC screening rates with the ultimate goal of reducing 
the incidence and mortality of CRC.
 Creation of a DOHMH Advisory Committee
An Advisory Committee, co-chaired by Drs. Harold Freeman and Sidney Winawer, was 
formed in 2002 to consider whether or not colonoscopy should be regarded as the preferred 
screening approach in NYC (Figure 1). The Advisory Committee reviewed available 
evidence related to screening reported in several guidelines3, 8–11, additional relevant 
papers3, 8, 11–13 and met with DOHMH cancer prevention professionals. Screening 
guidelines and their rationale were specifically tailored to the NYC health care environment, 
which included considerations of capacity, reimbursement and expected compliance by 
providers and the public. The following guidelines were adopted:
• Men and women age 50 years of age and older should undergo 
colonoscopy every 10 years.
• Annual fecal occult blood testing is recommended for individuals who are 
unable or unwilling to have a colonoscopy.
• People at high risk for colorectal cancer should begin screening with 
colonoscopy at age 40 or earlier.
Colonoscopy was recommended as the preferred test because: it examines the entire colon; it 
is relatively safe; polyps can be detected and removed to prevent cancer; and biopsies can be 
taken of suspicious lesions. Fecal occult blood testing (FOBT) was recommended as an 
alternative but considered less optimal because it is less sensitive and its impact on CRC 
morbidity and mortality requires annual testing over many years. It is thus programmatically 
more difficult to implement and monitor, compared with a single colonoscopy every 10 
years3, 4. A simple message encouraging one screening test was also considered to be more 
effective than a menu of options as recommended in most guidelines. DOHMH conducted a 
capacity study which confirmed that NYC’s healthcare system had sufficient resources to 
screen its ‘at risk’ population by colonoscopy5.
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 Launching of the C5 Coalition
In March 2003, a presentation was made by the Advisory Committee to a roundtable of 
healthcare providers, DOHMH staff, and stakeholders. The group agreed that there should 
be a coalition (C5) consisting of a broad representation of stakeholders in the community. 
The following mission statement was formulated:
• “The mission of the C5 Coalition is to partner with the NYC DOHMH to 
increase awareness and screening for colorectal cancer and adenomatous 
polyps in NYC men and women in order to reduce the incidence and 
mortality of this highly prevalent and preventable disease.”
From the onset, DOHMH and the Advisory Committee sought to establish clear goals:
• Increase colonoscopy screening rates for all New Yorkers age 50 or older 
and define targeted screening goals
• Eliminate racial and ethnic screening disparities
A number of sub-committees were formed. Table 1 lists the current and past sub-committees 
of C5. With its mission and goals delineated, several central questions were raised as 
DOHMH began to expand the membership of the Advisory Committee into a broader 
coalition of stakeholders (Table 2). Who were the key individuals and groups that would be 
critical to demonstrate the City’s commitment to the new screening policy? What resources 
(access to networks, to intellectual capital, and to financial support) could be mobilized to 
expand the reach and capacity of DOHMH? Which institutions and individuals would be 
critical for implementing initiatives, and who could provide a range of feedback evaluating 
the program and focus?
 Initiatives to Achieve Goals
Central to C5 efforts was an ongoing effort to engage all sectors in the awareness of the 
importance of CRC prevention and early detection through screening continually based on 
existing data. For example, in 2002, DOHMH launched the Community Health Survey 
(CHS), an annual, digitally-assisted, telephone survey of 10,000 randomly selected adults 18 
and older to understand the health status of New Yorkers. Data from these annual surveys 
provided crucial information to track critical outcomes such as a detailed demographic 
profile of who reported having a colonoscopy, and assessed progress against goals and 
targets including eliminating gender and racial disparities.
 Annual C5 Summit
The C5 Steering Committee, charged with overseeing all operations of C5, sought to engage 
as many stakeholders as possible in the development of C5 goals. An annual Summit was 
implemented to think critically as a unified community about C5 program initiatives. The 
Summit (http://c5nyc.org/) became an important venue for presenting updates of C5 
activities and obtaining critical feedback. Since the first Summit (November 2003), 
participation has grown to well over 200 attendees in 2014, many from around the country.
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Public education campaigns supported through DOHMH funding with some support from 
New York State (NYS) were targeted both at the general public and at specific underserved 
communities with low screening rates. These included recruiting celebrity spokespeople for 
radio and poster campaigns in the subway, on bus shelters, and throughout HHC hospitals; 
palm card distribution in check cashing offices; and extensive radio campaigns on selected 
ethnic radio stations. These campaigns were initially in English and Spanish. In addition, 
several NYC Health Bulletins encouraging colonoscopy screening were made available in 
other languages (i.e., Russian, Mandarin, and Cantonese) and widely distributed by 
DOHMH.
 Professional Education
Ongoing publications and outreach to health care providers about the need for colorectal 
cancer screening with the single message of colonoscopy screening every 10 years were 
implemented by DOHMH. Multiple postings in the City Health Information newsletter (e.g., 
June 2002, volume 27 (supplement 1); April 2009, volume 28 (supplement 2)) were sent to 
over 10,000 providers.
 DOHMH “Detailing Initiative”
A public health detailing program was initiated to promote the use of preventive services 
among primary care providers in NYC areas with a high incidence of CRC morbidity and 
mortality. Modeled after successful “detailing” strategies used by the pharmaceutical 
industry, trained DOHMH representatives delivered evidence-based messages and materials 
and provided brief, targeted messages to primary care offices and distributed “action kits” 
for providers and patients. Specific to CRC screening, representatives conducted 
approximately 640 site visits and 3940 one-on-one contacts during 2004, 2005 and 2008 to 
encourage adherence to NYC’s screening guidelines, and to promote colonoscopy screening 
referrals. Sites were located primarily in neighborhoods with either poor screening uptake, 
high poverty and/or large immigrant populations. The initial results from 2004 showed a 
significant increase from 26% to 42% in the proportion of providers who reported 
colonoscopy as their primary screening method14. When the campaign was repeated in 
2008, that proportion increased from 82% to 93%. Moreover, the proportion of offices with 
systems in place to promote colon cancer screening increased significantly from 52% to 
62%15.
 Patient Navigator Programs
Patient navigation, first described by Dr. Harold Freeman, involves the use of trained staff 
within the health care setting to help patients obtain necessary medical care16. While 
originally used within minority populations to ensure timely resolution of abnormal 
screening test findings, participating institutions in C5 adapted patient navigation to screen 
for CRC. The DOHMH secured significant foundation support from the New York 
Community Trust to develop a proof of concept that navigation could be successfully used to 
help patients complete a colonoscopy and also reduce the no-show rate. The navigator 
program has now been implemented in all 11 public hospitals and in 12 voluntary hospitals 
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throughout NYC. In addition, an extensive training program was developed, and is on-line 
for public access, including a one-week orientation and on-going seminars for navigators17. 
Further, the DOHMH developed an extensive database that permitted navigators to track 
their referred patients so that outcomes could be reported, and gaps in service addressed.
The business case for the CRC screening patient navigation program has been 
demonstrated18–20. For example, in a stakeholder hospital, C5 participants demonstrated that 
lay individuals (those over age 50 who have had their own colonoscopy) can be readily 
trained to serve effectively as peer patient navigators21. Modeling studies have demonstrated 
that navigating primarily African-American and Latino populations of low socioeconomic 
status from this same hospital is cost-effective22. This demonstration led to the development 
of additional training materials (including a focus on cultural issues) and a manual. The 
navigator program has been a consistent focus of C5, and on-going evaluation and updates 
on the use and value of navigation has encouraged robust support of the program.
 Direct Referral Initiative
Direct endoscopic referral (DERS) was developed to help streamline the colonoscopy 
referral process, including the elimination of the need for medically eligible patients to have 
a consultation prior to colonoscopy. DERS forms23 were developed by DOHMH in 
consultation with C5 members to encourage their use by primary care health professionals. 
Many hospitals in NYC have moved to a DERS system with some using the online form 
(www.nyc.gov/html/doh/downloads/pdf/cancer/cancer-colon-ders.pdf).
 NYC Colonoscopy Quality Initiative
As NYC’s screening rates continued to increase, it became apparent to DOHMH that it was 
necessary also to focus on ensuring the quality of the colonoscopies and that high quality 
exams be delivered in all screening settings in NYC. A working committee was formed to 
delineate the specifics of a Quality Initiative for NYC. This committee included stakeholders 
critical to such a program: several insurers, New York Society for Gastrointestinal 
Endoscopy (NYSGE), hospital based, ambulatory care, and office based gastroenterologists 
(GI), DOHMH and NYS DOH.
In response to national data showing the impact of colonoscopy quality metrics on the rate 
of interval cancers, the national GI professional associations undertook important quality 
tracking initiatives24. The American College of Gastroenterology and American Society of 
Gastrointestinal Endoscopy joined together in 2009 and launched the GI Quality 
Improvement Consortium, Ltd (GIQuIC). This national GI endoscopy data repository allows 
for storage of endoscopy quality measures for GI endoscopists and is provided through 
downloads from their respective endowriters. After the C5 Quality sub-committee proposed 
a partnership with GIQuIC24, NYC sites were added to that database, and DOHMH 
developed tailored benchmarking reports for its participating gastroenterologists.
In 2011, the NYC Colonoscopy Quality Benchmarking Group (CQBG) was created with 
support from the CDC and the NYS DOH and led by the DOHMH in partnership with C5 
and NYSGE. The campaign recruited hospitals, private practices and ambulatory surgery 
centers. Practice sites participated voluntarily. Over a 3-year period, more than 230 
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gastroenterologists were recruited. DOHMH provides sites with de-identified quarterly 
benchmarking reports tracking evidence-based quality measures, which allows for 
comparison of endoscopist performance within and between sites.
 Targeted programs to address inequalities
Since the inception of NYC’s CRC screening campaign a decade ago, the elimination of 
inequalities has been a core goal. Strategies were data driven, with annual analysis of the 
DOHMH Community Health Survey to identify and monitor screening inequalities for a 
range of subgroups. As certain inequalities were eliminated, others persisted or emerged, 
and strategies evolved to respond. We highlight here a few initiatives that illustrate how 
these strategies developed and evolved.
Although in 2003 significant gaps existed between the screening rates for black, white, 
Asian and Hispanic New Yorkers who had timely screening by colonoscopy7, by 2007, the 
screening gaps between blacks, whites and Hispanics were eliminated, with the gap for 
Asian New Yorkers closing in 2010 (Figure 2)7. An extensive outreach campaign at NYC’s 
public hospital system, HHC, which serves 1.3 million patients annually, the majority of 
whom are black, Hispanic and Asian, contributed significantly to the elimination of racial 
and ethnic disparities. Today all these groups are screened on par7.
 Targeting the Russian and Chinese Speaking Communities
As racial and ethnic disparities were eliminated, others inequalities were identified. Utilizing 
the NYC Community Health Survey 2010 data, DOHMH analyzed screening trends 
geographically, mapping neighborhoods and their screening rates. The analysis revealed 
significant screening disparities based upon ‘language spoken at home.’ Specifically, in 
2009, the screening rates for the Russian and Chinese speaking community were 
significantly lower than those for English or Spanish speaking New Yorkers25. Overlaying 
the geographic and demographic data, neighborhoods were identified that had both low CRC 
screening rates and a high concentration of Russian and Chinese speakers. Culturally and 
linguistically tailored interventions were then designed and implemented in those 
neighborhoods, including an aggressive media campaign with posters and text tested by 
focus groups, ethnic radio and newspaper campaigns, and provider education.
 Leveraging Endoscopy Centers to Provide Free Colonoscopy Screening
A recently launched DOHMH project, the ‘Community Cares Project’, grew out of a 
recommendation from the newly formed C5 Community Health Center Sub-committee 
(CHC). The ‘Community Cares Project’ focuses on NYC’s uninsured, a subgroup screened 
at a rate significantly lower than those who are insured26. In this project, free-standing 
endoscopy centers provide free colonoscopy screenings to uninsured patients referred by 
CHCs. The project leveraged a NYS ‘charity care’ requirement27 for certain endoscopy 
centers, and harnessed the desire and dedication of providers to give back to their 
community. On the CHC side of the equation, the project aligned with an enhanced focus on 
CRC screening, as CRC screening rates became a reportable metric for Federally Qualified 
Health Centers in 2012.28 In its pilot year, two participating endoscopy centers performed 
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over 500 screening colonoscopies on uninsured patients referred from five CHCs29. Thus far 
in year two, an additional 10 sites have joined, including seven new endoscopy centers. 
Additionally, quality improvement strategies are being developed and tested in the CHCs.
 Funding for C5 Initiatives
Most of C5’s work was made possible by a willingness among the many constituents of the 
NYC health care community to be active participants and to work synergistically. NYC 
DOHMH, NY State and the CDC all provided significant public support, as well as 
additional private support numerous foundations. Physicians and hospital systems redoubled 
their efforts to increase screening colonoscopy by whatever means and resources worked in 
their local environment. Several insurance companies developed outreach initiatives to their 
members along with registries to identify unscreened patients for their physicians. 
Community based organizations focused their resources on CRC prevention. Several centers 
redesigned their endoscopy units to create greater efficiency and implement direct referral 
systems. Individual hospitals assumed leadership roles. For example, the Mount Sinai 
Medical Center launched innovative and carefully studied patient navigation programs 
funded by the National Cancer Institute20, 21, 30 and Columbia Presbyterian Hospital 
developed an efficient DERS program23. An important amount of the resources needed to 
support these efforts was generated by the organizations themselves, and not through an 
infusion of public funding.
The American Cancer Society (ACS) developed and managed an important citywide 
initiative to provide screening colonoscopy to uninsured and underinsured New Yorkers. 
Launched in 2004, the ACS Colonoscopy Screening Program for the Uninsured was funded 
by the NYC Council and has provided over 20,000 free screening colonoscopies to 
uninsured New Yorkers to date. ACS Advocacy staff conducted intensive annual campaigns 
to secure uninterrupted funding from the NYC Council for this key program. Further, in 
2004, ACS also led the effort to obtain voluntary agreement from most NYS Commercial 
Health Plans to reimburse for CRC screening with colonoscopy.
 “Lessons Learned” From the C5 Experience
The implementation and evolution of C5 may offer some generalizable principles and 
approaches that could help guide the development of similar coalitions in other 
communities. Like the proposed Cascade model in which screening guidelines are driven by 
available resources as well as medical evidence31, communities seeking to develop a C5-like 
organization must build it using their unique resources. The following lessons are distilled 
from the NYC experience:
• Identify High Level Champions and Encourage Distributed Leadership: 
NYC’s effort was spearheaded by the Commissioner of the NYC 
DOHMH with very strong support from the President of HHC. The initial 
Advisory Panel included leading international experts on CRC screening. 
This core group of very high level, public and private sector experts was 
joined by leadership from multiple sectors which sustained the growth of 
C5 and NYC’s screening initiatives.
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• Engage a convening entity: DOHMH was the convening entity and 
continues to provide significant, sustained resources to anchor C5.
• Define and revise goals: Goals were defined at the inception of the 
initiative and were continually revised based upon emerging data and 
trends. NYC’s dual goal of both increasing screening city-wide and 
eliminating screening inequalities informed and drove all strategies. A 
laser-like, sustained focus on screening inequalities has been essential.
• Be data-driven: Various data sources were used to track progress and gaps 
in care that informed new strategies. These included NYC’s Community 
Health Survey, Uniform Data System (UDS), NYS Quality Assurance 
Reporting Requirements (QARR), GIQuIC, NYS Cancer Registry, and the 
DOHMH Colonoscopy Navigator Database.
• Identify trends and create synergies: Emerging healthcare system trends 
were identified to create synergies that promoted NYC’s goals.
– NYC’s initial focus on colonoscopy screening was a policy 
decision that was based on the inclusion of colonoscopy as 
a screening option in national guidelines and the decision 
of payers to provide reimbursement.
– Patient navigation has now been demonstrated to be 
integral to the success of screening colonoscopy programs.
– Colonoscopy quality – after identifying that there was a 
need for quality improvement, NYC leveraged the work of 
the national GI associations, including its partnership with 
GIQuIC.
– NYS public health law provision requiring free-standing 
endoscopy centers (ambulatory surgical centers) to 
perform services for the medically underserved was 
utilized to screen the uninsured.
– Leadership continuously identified strategies to take 
advantage of incentives embedded in the evolving models 
for payment system reform, such as Patient Centered 
Medical Homes, Accountable Care Organizations, Pay for 
Performance.
– Healthcare Effectiveness Data and Information Set 
(HEDIS) and QARR quality measures included 
colonoscopy screening.
• Establish an Organizational Structure: The organizational structure (with 
sub-committees and working groups) was program-driven and flexible, 
and supported evolving goals. In addition, the structure was a vehicle to 
engage stakeholders’ participation, report progress and receive alerts to 
new challenges, and sustain commitment.
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• Engage Multi-Sector Stakeholders: Multi-sector stakeholders (Table 2) 
who were invested in achieving the goals, such as provider systems, health 
plans, and advocacy and community based organizations, were recruited to 
C5.
• NYC-specific assets: The success of C5 clearly has depended in part on 
infrastructure features that are specific to NYC.
– NYC’s safety net healthcare system - Without this far 
reaching high quality healthcare system serving NYC’s 
underserved communities, the elimination of racial and 
ethnic disparities would not have been possible
– NYC Council funding of colonoscopies for underinsured 
adults, along with significant ACS operational support.
– NYS’s Emergency Medicaid Program – if a CRC is 
detected by screening, this program provides coverage for 
CRC treatment, regardless of insurance or whether an 
individual is undocumented. Given NYC’s extensive and 
essential undocumented population, this benefit has been 
vital.
– The high concentration of gastroenterologists that provide 
significant capacity for colonoscopy screening helped 
make this possible.
– Strong health department provides sustained, significant 
support.
– Extensive voluntary hospital systems, with strong 
academic commitment and which value physician 
engagement and research
• Challenges:
– Efforts to sustain active engagement and support from the 
primary care provider community have met with uneven 
success. The enduring competing priorities facing primary 
care providers present challenges to achieving high rates of 
cancer screening, including CRC screening.
– There remains a lack of adequate resources to screen the 
uninsured. Despite innovative, significant local programs, 
and NYS’s Cancer Services Program, the screening gap 
for the uninsured remains significant. While the 
Affordable Care Act has helped lower the number of 
NYC’s uninsured, this legislation does not provide 
coverage to the undocumented community.
Itzkowitz et al. Page 10













– Data are needed regarding the outcome of those who are 
found to have CRC or advanced adenomas with respect to 
the continuum of care.
– While a business case has been developed for endoscopy-
based patient navigation18, 20 no corresponding sustainable 
model has yet been developed for primary care.
– Efforts to include navigators as a sustainable resource have 
failed, requiring independent funding of these programs.
– There is a continual need for securing current and new 
resources in a climate of dwindling resources.
– Increases in CRC screening rates have leveled off. 
Underlying factors need to be studied in order to reassess 
strategies.
– The preference for colonoscopy provides a strong, clear, 
unified message. However, for systems such as 
Community Health Centers that may implement fecal 
occult-blood based programs, C5 has so far provided less 
support.
 Conclusions
The dramatic increase in NYC screening colonoscopy rates among average-risk men and 
women from 42% (2003) to 62% (2012) and now at 69% (2013) were advanced by this 
series of sequential steps. Foremost was that CRC screening was made a top priority by both 
the NYC Commissioner of Health and the President of NYC HHC. Second, a mission 
statement and clear goals were established. Third, a citywide coalition was organized, a 
broad range of stakeholders were engaged, and a structure was established. Fourth, many 
programs were developed and adapted to increase screening in all NYC communities and to 
eliminate inequalities. Fifth, program strategies and goals evolved as new needs were 
defined. Finally, metrics were put in place to monitor progress and provide positive feedback 
to all stakeholders.
Our goal in describing the history of the program is to provide a description of the multiple 
elements of NYC’s Colonoscopy Screening Initiative, its evolution, and the important role of 
the DOHMH/C5 partnership. We have learned that this needs to be a dynamic process that is 
flexible as new concepts of CRC prevention evolve (e.g., chemopreventive agents, new 
technology such as new screening tests with high sensitivity for CRC and advanced 
adenomas, new genetic evidence) and the health care landscape changes which will have 
further impact on resources and sustainability. The impact that increased screening might 
have on the incidence and mortality of CRC in NYC, especially as it relates to current 
disparities, will be the subject of a future report. We anticipate that these developments will 
have an impact nationally and will influence future directions of the DOHMH/C5 program 
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locally in NYC. Hopefully, this will result in significant reduction in the incidence and 
mortality of CRC.
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Percentage of NYC individuals ≥ 50 years old who received colonoscopy within the last 10 
years by race/ethnicity; 2003-2013. Source: New York City Community Health Survey
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Steering Committee • Oversee C5 activities and committees
• Strategic planning
• Recommendations to C5 and DOHMH leadership
Screening Guidelines • Develop NYC-specific CRC screening guidelines.
• Review evidence on annual basis
• Update guidelines
Summit Planning • Review progress of C5 and national CRC screening efforts
• Develop program/speakers for Summit
• Obtain input from C5 members
• Provide updates of C5 activities to members
Communications • Develop and implement CRC Awareness Month campaigns in March
• Inform stakeholders of C5 events and progress.
Colonoscopy Quality/Benchmarking • Develop network of participating endoscopy units in NYC
• Track the outcomes of colonoscopies performed
Community Health Centers • Engage primary care providers in C5 efforts
• Promote patient education for CRC screening
PAST
Direct Endoscopy Referral System 
(DERS)
• Develop systems to directly refer patients for colonoscopy
• Implement and track use of DERS
“Plateau” Committee • Assess factors in the leveling-off of NYC’s CRC screening rate
• Propose strategies to increase the rate
Health Care Access • Partnere with Health Plans to explore the influence of care coordinators 
on screening rates
Ambassador Program • Have physician leaders reach out to other physicians to promote the C5 
message and enhance CRC screening
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Table 2
C5 Stakeholders
Type of Participant C5 Partners
Physicians • Gastroenterologists, primary care providers, gynecologists, surgeons




• Community Health Centers
• Ambulatory Surgery Centers
Insurers with extensive NYC membership • Emblem Health
• Aetna
• MetroPlus
• Union health benefit plans (e.g. Local 1199 Benefit and Pension Fund)
Professional Organizations • New York Society for Gastrointestinal Endoscopy
• American College of Gynecology
Health Departments • NYC Department of Health and Mental Hygiene
• NY State Department of Health
Advocacy Groups • American Cancer Society
• Colon Cancer Challenge Foundation
• Center for Immigrant Health
Survivor Organizations • Colon Cancer Alliance
Patient Navigators • Colonoscopy Navigator network
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